Merck KGaA drops BTK inhibitor evobrutinib, marking end of road for blockbuster dreams

It’s been a quick fall from grace for evobrutinib. Only months ago, Merck KGaA was outlining hopes for a major commercialization push for the BTK inhibitor—and now the German pharma has dropped the drug completely.